BREAKING NEWS: New drug approved by the FDA for Duchenne muscular dystrophy. Learn more about this new treatment option.

Medical Educational Resource

We're accelerating the delivery of treatments and cures.

The Evolving Therapeutic Landscape for Becker Muscular Dystrophy: An Update - Part 1

Activity Snapshot

Activity Type: 
Live, Virtual Webinar
Release Date: 
Thursday, June 8, 2023
Sponsor Information: 

This Industry Update Webinar is sponsored by EdgeWise.

Faculty

Activity Overview: 

 

Watch Now - password: TjvbTa?3IUW

June 8, 2023
12 p.m. ET
Duration: 30 minutes

Becker muscular dystrophy (BMD) is a serious dystrophinopathy. Declining function can begin at different ages, but once it begins, Becker patients are on an irreversible path to losing muscle and consequently, function.

We will discuss the following:

  • The clinical course and natural history of Becker muscular dystrophy: perceptions and current data
  • The personal experience of living with Becker muscular dystrophy
  • The emerging clinical trial landscape: Are we ready? What’s next?

Panelists

  • Chair: John Wing, PhD, Sr Director Medical Affairs, Edgewise Therapeutics
  • Barry J. Byrne, MD, PhD, Associate Chair of Pediatrics and Director of the Powell Gene Therapy Center at the University of Florida.
  • Nevin Steiner, Patient Advocate
  • Joanne Donovan, MD, PhD, Chief Medical Officer, Edgewise Therapeutics